

出國報告（出國類別：開會）

## 2023 年美國藥物經濟暨效果研究學會 (ISPOR)報告

服務機關：高雄榮民總醫院/藥學部

姓名職稱：梁君安/藥師

派赴國家：美國波士頓

出國期間：2023/05/05-2023/05/12

報告日期：2023/05/23

## 摘要

藥物經濟暨效果研究學會(ISPOR)，是非營利國際性的組織，致力於發現科學、影響政策進而實踐。該學會使命是促進健康經濟學和結果研究，增進全球健康決策。今年，有超過 110 個國家、4500 人與會，提供政府官員、醫療機構至病人代表等不同身分、不同觀點。

本次主題為「影響創新、價值和醫療保健決策」，描述後疫情時代讓世界反思:如何加速及合併不同醫療產業對健康議題的研究?利用人工智慧輔助增進醫療發展的困難與現況。包含短期課程、大會演講、ISPOR 論壇、教育訓練講座、案例討論、學術論文發表、壁報導覽等。首創實體會議合併數位講座，讓未能出席與會及想同時聽到多場講座的參與者有新選擇。帶給世界不同角落為健康議題努力的戰士不同視野、不同觀點。

**關鍵字** 藥物經濟暨效果研究學會、健康經濟、果效研究。

# 目次

一、目的 .....	4
二、過程 .....	4
三、心得及建議 .....	5
附錄 .....	7

## 一、目的

成立於 1995 年藥物經濟暨效果研究學會 (ISPOR)，每年於美洲、歐洲及亞洲舉行三場全球性的會議，場場聚集上百國家、幾千人與會，從政府醫療決策高層、廠商代表、醫療人員、研究學者至病人代表，以不同觀點討論不同國家健康經濟政策的決策原因與關鍵，討論主題十分廣泛從：藥物療效與安全性評估、藥物經濟效益比較、藥物上市後安全監測策略、研究方法討論、大數據資料庫應用、人工智慧輔助等，邀請每個領域專家分享讓不同專業了解彼此的立場及增進健康相關研究的發展，進而影響政府政策制定、提升全球健康保健策略。

## 二、過程

本次會議日期自 2023 年 5 月 7 日至 5 月 10 日，大會主題為「影響創新、價值和醫療保健決策」(Impacting Innovation, Value, and Healthcare Decision-Making)。於美國波士頓舉行，前兩天歷經 16 小時從台灣飛至紐約再搭火車經 4 個半小時抵達波士頓後，終於抵達會議現場。會議前一天屬於短期課程時期針對特定主題進行課程介紹，包含：Introduction to Machine Learning Methods、Developing Decision-Grade Real-World Evidence、Introduction to Patient-Reported Outcomes Assessment: Instrument Development & Evaluation 等快 10 個主題相關討論，每個都很吸引人，但礙於時間因素只能擇一參與，其中 Patient-Reported Outcomes Assessment 的課程中提及，在進行臨床研究不論是藥品有效性或安全性都需要結果的指標來衡量介入的成效，然而並非所有指標都能以客觀數據進行呈現，因此，這門課提及如何設計運用病人報告的結果來呈現研究成效、結果的評估及測量工具的運用，讓藥品安全性有效性的資料呈現有更多元的指標評估。

第二天開始便進入正式會議，各國學者、醫療人員、廠商、病人代表等紛紛出席參與，在海報展示中，由於展示海報眾多故分 3 天 5 梯次進行海報展示，此外，也有海報展演的環節，由特定的海報作者帶領大家遊歷介紹本次海報中有特色的作品，此外，也可以在討論的環節與有興趣海報的作者進行交流，其中一件海報在討論在不同族群降血壓藥物的介入強弱是否有可參考依據，這是非常有趣且實用的研究，相信不論在世界上哪個國家都有降壓藥物給付的需求，然而在五花八門的血壓品項中，通常依醫療人員專業替民眾挑選一項以上不同機轉的藥物品項，然而，卻沒有很一致性的證據證明哪些族群使用特定血壓藥物品項有益，因此，這個研究不論給醫療人員甚至政府單位對於給付藥品一些依據與決策參考，對於如何在有限醫療資源

中最大化治療效果非常有助益。

第三天一樣迎來各式各樣的課程資訊及數以百計的海報展演，其中一場 BioNTech 疫苗討論令人印象深刻且充滿震撼，在後疫情，全世界感受到醫療發展速度與疾病拓展的衝擊，傳統而言，一件藥物從臨床前試驗到上市需要將近十年時間，然而，這疫情喚醒世界對藥物開發急迫性的知覺，如何在有限時間中最大效益整合研究成效、蒐集研究結果變得格外重要，BioNTech 廠商與施打疫苗管道之一的 CVS 藥局合作，CVS 是美國連鎖的藥局，透過疫苗施打後民眾提供的電子郵件發出試驗邀約，邀請民眾回報疫苗施打後安全性問題及後續若確診的症狀相關資料，由藥商與連鎖藥局彼此合作得到疫苗後續安全性及有效性的相關資料，這項研究提供在場許多藥廠甚至研究人員在資料取得的可能性的想法，也更加確信研究中跨場域合作的必要。

會議最後一天只有半天的課程但是一樣精彩可期，其中人工智慧(AI)是現在最熱門的議題，尤其如何運用 AI 判讀文字型的病歷資訊？提供除了客觀數據以外的結果幫助研究的進行；或者 AI 使用上到底站在什麼樣的角色？是輔助醫療人員診斷與治療還是取代？都是有趣的議題，但當今 AI 雖然發展得很蓬勃但依然有運用上的限制，例如：如何整合不同語言的資訊，翻譯過程中的誤差等等，都使得 AI 產品推廣至全世界時應用性的挑戰。

### 三、心得及建議

(一)心得：本次會議通過與不同國家身分代表的專業會議獲得許多新的做法，首先、設備的先進令人印象深刻，從報到到會議提醒都以電子化的方式進行，大大降低人力；此外，會議中也安排兩種以上不同觀點的業界人士進行討論，提升大家對於同一議題不同面向的思考；最後，在不同國家、團隊的作品及海報展示演講中，得知不同國家在決策考量觀點與面向。

(二)會議中得到以下幾個想法及建議：

1. 運用 AI 提升研究類型廣度：目前研究以資料庫進行往往局限於數值型資料，病歷回溯又曠日廢時，若能與 AI 相關人才合作，將能將文字相關病歷資訊轉化成可分析運用的資料，提升資料運用的廣度；
2. 增加不同醫療單位合作：院內資訊局限於病人入院就醫時間段的相關資訊，若能與其他醫療機構、藥局、長照單位合作，能增加追蹤資料的全面性與完整性；

3.持續派員參加國際會議:透過國際會議能了解國際最新趨勢、相關新知與政策走向、最新研究方法與應用，能帶來更新做法與創意。

# 附錄

## 附錄一-議程

<p><b>Sunday, May 7</b> <span style="float: right;">OPEN ALL</span></p> <p><b>7:00AM - 8:00PM</b> <b>REGISTRATION HOURS</b> Sponsored by Center Research SPONSOR </p> <p><b>8:00AM - 11:00PM</b> <b>SHARED COURSE WORKSHOP SESSIONS</b></p> <ul style="list-style-type: none"> <li>Developing Decision Grade Real-World Evidence</li> <li>Introduction to the Design and Statistical Analysis of Observational Studies of Treatment Effects Using Retrospective Data Sources</li> <li>Elements of Pharmaceutical/Biotech Pricing</li> <li>Applied Cost Effectiveness Modeling With R</li> <li>A Health Economics Approach to US Value Assessment Frameworks</li> <li>The Delphi Panel—From Standard to Adaptive HEOR Insights</li> <li>Introduction to Machine Learning Methods</li> <li>Introduction to Patient Reported Outcomes Assessment: Instrument Development &amp; Evaluation</li> </ul> <p><b>8:00AM - 10:00PM</b> <b>SMART COURSE FULL DAY</b></p> <p>Introduction to Health Economics and Outcomes Research</p> <p><b>10:00PM - 10:30PM</b> <b>BRILL</b></p> <p>Health services research for you here in Dublin! Discover the HEOR in your world at a healthy weekend.</p> <p><b>1:00PM - 5:00PM</b> <b>SMART COURSE AFTERNOON SESSIONS</b></p> <ul style="list-style-type: none"> <li>Case Studies in Pharmaceutical/Biotech Pricing II</li> <li>Benefit Risk Assessment in Medical Product Development</li> <li>Core Concepts and Approaches to Early Stage Health Technology Assessment</li> <li>Risk Sharing/Performance Based Arrangements for Drugs and Other Medical Products</li> <li>Network Meta-Analysis in Relative Effectiveness Research</li> <li>Advanced Decision Modeling for Health Economics Evaluations</li> <li>Leveraging Real-World Evidence to Support Patient Safety Monitoring After Clinical Trials</li> </ul>	<p><b>Monday, May 8</b> <span style="float: right;">OPEN ALL</span></p> <p><b>7:00AM - 8:00PM</b> <b>REGISTRATION HOURS</b> Sponsored by Center Research SPONSOR </p> <p><b>7:30AM - 8:30AM</b> <b>MORNING COFFEE SERVICE</b></p> <p><b>8:30AM - 9:00AM</b> <b>PLENARY SESSION</b></p> <p>100 Welcome and First Plenary Session</p> <p><b>9:00AM - 9:45PM</b> <b>POSTER AND EXHIBIT HALL OPENS</b></p> <p><b>9:00AM - 12:00PM</b> <b>AM COFFEE BREAK</b> Location: On-Campus Atrium</p> <p><b>9:00AM - 1:00PM</b> <b>POSTER SESSION 1</b></p> <ul style="list-style-type: none"> <li>Clinical Outcomes</li> <li>Economic Evaluation</li> <li>Epidemiology &amp; Public Health</li> <li>Health Policy &amp; Regulatory</li> <li>Health Service Delivery &amp; Process of Care</li> <li>Health Technology Assessment</li> <li>Medical Technologies</li> <li>Methodological &amp; Statistical Research</li> <li>Organizational Practices</li> <li>Patient-Centered Research</li> <li>Real-World Data &amp; Information Systems</li> <li>Study Approaches</li> </ul> <p><b>11:00AM - 11:00AM</b> <b>MEMBER GROUP MEETING</b></p> <p>Digital Health Special Interest Group Open Meeting</p> <p><b>11:00AM - 11:00AM</b> <b>CLOSED MEMBER GROUP MEETING</b></p> <p>OPOR Board Chapter Meeting</p>	<p><b>10:00AM - 11:00AM</b> <b>BRISQ/ACUTE: IP, WS, &amp; ORS</b></p> <ul style="list-style-type: none"> <li>101. Has the Bridge Between Regulatory and HTA Agencies Collapsed? Adapting to the American Unilateral Surrogate Outcomes in Early Stage Cancer Trials</li> <li>102. Is it Time for Wearable Technologies to Replace Patients Reported Outcomes? in Rare Neurovascular Diseases Are We Seeing a Paradigm Shift?</li> <li>103. Patient-Centred Solutions: How Can We Balance Value, Evidence and Stakeholder Needs for Digital Therapeutics?</li> <li>104. RWE and Health Disparities in HTA: Is Transparency the Main Barrier for Equity Data Sharing across Borders?</li> <li>105. What Would (Should) CMS Do? A Debate on Options for Drug Price Negotiations</li> <li>106. Marginal Structural Models for Causal Inference Using Observational Healthcare Data: Real-Worlds and Case Studies</li> <li>107. Use of Real-World Data in the Health Technology Assessment of Pharmaceuticals and the Design and Maintenance of a Fostering Registry of Experience</li> </ul> <p><b>10:00AM - 11:00AM</b> <b>PODOLM SESSION</b></p> <ul style="list-style-type: none"> <li>108. Economic Evaluation of Rare Diseases</li> <li>109. Health Equity in HEOR</li> </ul> <p><b>10:00AM - 11:00AM</b> <b>CASE STUDIES</b></p> <ul style="list-style-type: none"> <li>110. Outcomes Case Studies</li> </ul> <p><b>11:00AM - 1:00PM</b> <b>LUNCH</b></p> <p>Bring your lunch to lunch in our meeting room located in the atrium. All the food and beverage that you will be provided in accordance with your dietary requirements.</p> <p><b>11:00AM - 12:00PM</b> <b>NEW ATTENDEE/NEW MEMBER WELCOME EVENT</b></p> <p>The Membership team will be on hand to provide you with everything you need to know about the event, including how to register, and highlight the many ways you can give your involvement with HEOR.</p> <p><b>11:00AM - 12:00PM</b> <b>POSTER TOURS</b></p> <ul style="list-style-type: none"> <li>111. Cardiovascular and Diabetes/Endocrine/Metabolic Disorders Poster Tour</li> <li>112. Patient-Centered Research Poster Tour</li> </ul> <p><b>11:00AM - 12:00PM</b> <b>FACT FACTS</b></p> <ul style="list-style-type: none"> <li>114. Plain Language Summaries</li> </ul> <p><b>11:00AM - 12:00PM</b> <b>EXHIBIT HALL THEATER</b></p> <ul style="list-style-type: none"> <li>113. Conducting Qualitative Interview Research in the Context of Clinical Trials: Opportunities and Challenges Involved</li> </ul>
<p><b>1:00PM - 2:00PM</b> <b>MEMBER GROUP MEETING</b></p> <p>Education Council Meet Up Meeting</p> <p><b>1:00PM - 2:00PM</b> <b>MEMBER GROUP MEETING</b></p> <p>Statistical Methods in HEOR Open Meeting</p> <p><b>1:00PM - 2:00PM</b> <b>BRISQ/ACUTE: IP, WS, &amp; ORS</b></p> <ul style="list-style-type: none"> <li>125. Blazing the Trail for Digital Health Innovation: Resources and Complexes Based on a Digital Health Application for Dementia Family Caregivers</li> <li>126. Guiding Better Value Assessments for Health Services and Procedures</li> <li>127. What is 'Fair' Access for Orphan Drugs in the US?</li> <li>128. Alternative Network Meta-Analysis Methods in the Presence of Non-Proportional Hazards</li> <li>129. Can US Healthcare Data Inform HTA in Other Parts of the World?</li> <li>130. Patient-Centred Preference Assessment on Treatment-Process Attributes: Challenges and Opportunities</li> </ul> <p><b>1:00PM - 2:00PM</b> <b>OPOR STUDENT NETWORK SESSION</b></p> <ul style="list-style-type: none"> <li>131. Exploring Alternative Payment Models for Medications: Disrupting Traditional Payment Methods</li> </ul> <p><b>1:00PM - 2:00PM</b> <b>PODOLM SESSION</b></p> <ul style="list-style-type: none"> <li>132. Long Term COVID-19 and Mental Health</li> <li>133. Modeling Methods in Oncology</li> </ul> <p><b>1:00PM - 2:00PM</b> <b>SPOTLIGHT SESSION</b></p> <ul style="list-style-type: none"> <li>134. Medicare Drug Price Negotiation in the US: Implications, Evidence Needs, and Unanswered Questions</li> </ul>	<p><b>1:00PM - 2:00PM</b> <b>EXHIBIT HALL THEATER</b></p> <ul style="list-style-type: none"> <li>135. PROMEDIA - Make Better Decisions Using Innovative Comparative Effectiveness Methods, Cytel's Innovative Software System</li> </ul> <p><b>1:00PM - 4:00PM</b> <b>POSTER TOURS</b></p> <ul style="list-style-type: none"> <li>136. Immunology Research in HEOR Poster Tour</li> <li>138. Pricing Reimbursement Poster Tour</li> </ul> <p><b>1:00PM - 4:00PM</b> <b>DISCUSSION GROUPS</b></p> <ul style="list-style-type: none"> <li>140. Blazing the Trail for Digital Health Innovation: Resources and Complexes Based on a Digital Health Application for Dementia Family Caregivers</li> <li>141. Alternative Network Meta-Analysis Methods in the Presence of Non-Proportional Hazards</li> </ul> <p><b>1:00PM - 4:00PM</b> <b>MEMBER GROUP MEETING</b></p> <p>Patient-Centered Special Interest Group Open Meeting</p> <p><b>1:00PM - 4:00PM</b> <b>OPOR FORUMS</b></p> <ul style="list-style-type: none"> <li>147. Considerations for Conducting Exploratory, Descriptive, and Other Non-HEOR Studies Using Real-World Data - Relieving Quality, Purpose, and Resources</li> <li>138. What is an Open-Source Model? Forging a Path to Belief</li> <li>139. Towards Greater Relevance for HEOR: An HEOR Younger Project</li> </ul> <p><b>1:00PM - 4:00PM</b> <b>EDUCATIONAL SYMPOSIUM</b></p> <ul style="list-style-type: none"> <li>140. Communicating the Value of Innovation: Pushing Beyond the Clinical Industry of Clinical Benefits</li> <li>142. Representative vs. Representational</li> </ul> <p><b>1:00PM - 4:00PM</b> <b>POSTER SESSION 2</b></p> <ul style="list-style-type: none"> <li>Clinical Outcomes</li> <li>Economic Evaluation</li> <li>Epidemiology &amp; Public Health</li> <li>Health Policy &amp; Regulatory</li> <li>Health Service Delivery &amp; Process of Care</li> <li>Health Technology Assessment</li> <li>Medical Technologies</li> <li>Methodological &amp; Statistical Research</li> <li>Organizational Practices</li> <li>Patient-Centered Research</li> <li>Real-World Data &amp; Information Systems</li> <li>Study Approaches</li> </ul> <p><b>10:00AM - 10:00AM</b> <b>GET TO KNOW OPOR'S FACULTY MEMBERS</b></p> <p>The Membership team will be on hand to provide you with everything you need to know about the event, including how to register, and highlight the many ways you can give your involvement with HEOR.</p> <p><b>10:00AM - 11:00AM</b> <b>BRISQ/ACUTE: IP, WS, &amp; ORS</b></p> <ul style="list-style-type: none"> <li>201. A Comparison of HEOR Research and Research Analytics</li> <li>202. Enabling Patient Access to Digital Therapeutics - The Optimal Approach?</li> <li>203. OPOR Latin America Health Policy Update</li> </ul>	<p><b>Tuesday, May 9</b> <span style="float: right;">OPEN ALL</span></p> <p><b>7:00AM - 8:00PM</b> <b>REGISTRATION HOURS</b> Sponsored by Center Research SPONSOR </p> <p><b>7:30AM - 8:30AM</b> <b>MORNING COFFEE SERVICE</b></p> <p><b>8:30AM - 9:00AM</b> <b>PLENARY SESSION</b></p> <p>100 Second Plenary Session</p> <p><b>9:00AM - 9:45PM</b> <b>POSTER AND EXHIBIT HALL OPENS</b></p> <p><b>9:00AM - 12:00PM</b> <b>AM COFFEE BREAK</b> Location: On-Campus Atrium</p> <p><b>9:00AM - 1:00PM</b> <b>POSTER SESSION 3</b></p> <ul style="list-style-type: none"> <li>Clinical Outcomes</li> <li>Economic Evaluation</li> <li>Epidemiology &amp; Public Health</li> <li>Health Policy &amp; Regulatory</li> <li>Health Service Delivery &amp; Process of Care</li> <li>Health Technology Assessment</li> <li>Medical Technologies</li> <li>Methodological &amp; Statistical Research</li> <li>Organizational Practices</li> <li>Patient-Centered Research</li> <li>Real-World Data &amp; Information Systems</li> <li>Study Approaches</li> </ul> <p><b>10:00AM - 10:00AM</b> <b>GET TO KNOW OPOR'S FACULTY MEMBERS</b></p> <p>The Membership team will be on hand to provide you with everything you need to know about the event, including how to register, and highlight the many ways you can give your involvement with HEOR.</p> <p><b>10:00AM - 11:00AM</b> <b>BRISQ/ACUTE: IP, WS, &amp; ORS</b></p> <ul style="list-style-type: none"> <li>201. A Comparison of HEOR Research and Research Analytics</li> <li>202. Enabling Patient Access to Digital Therapeutics - The Optimal Approach?</li> <li>203. OPOR Latin America Health Policy Update</li> </ul>

<p><b>11:00AM - 12:00PM MEMBER GROUP MEETING</b></p> <p>Meeting for Latin America Consortium Stand-Up Meeting</p>	<p><b>1:00PM - 2:00PM CLOSED MEMBER GROUP MEETING</b></p> <p>ISPOR Mexico Chapter Meeting</p>	<p><b>1:00PM - 4:00PM DID FACTS</b></p> <p>245. HCR/JOB Market and Workforce Trends: Insights from a Recruiter</p>
<p><b>11:00AM - 12:00PM POSTER TOURS</b></p> <p>211. Oncology Poster Tour</p> <p>212. Student Research Spotlight Poster Tour</p>	<p><b>1:00PM - 2:00PM BREAKOUTS (IF, WS &amp; OR)</b></p> <p>225. Overcoming the Complex Landscape of Infectious Diseases: How Can Members Best Choose the Level of Complexity that Increases Both Investment in Technology and Model Interpretability?</p> <p>226. Disinvestment in Healthcare Systems: The Why, What, When, and How?</p> <p>227. Inflation Reduction Act (IRA) Negotiation: Closer to Government Price Setting or Traditional HTA?</p> <p>228. Transparency in Health Technology Assessment: How Much is Too Much?</p> <p>229. SPUR (Share Preference of Personal Utility Functions): Understanding What Brings Value to the Individual</p> <p>230. The Reality of Target Trial Emulation for Medical Decision Making and HTA Recommendations - Is the Gap Between Academic and HTA Applications Too Wide?</p>	<p><b>2:00PM - 4:00PM EXHIBIT HALL THEATER</b></p> <p>244. Across the Continuum of Real-World Data Use Cases in Oncology: From Early Signals to Regulatory Decision Making</p>
<p><b>11:00AM - 12:00PM DID FACTS</b></p> <p>214. Building Your Social Media Presence</p>	<p><b>1:00PM - 2:00PM ISPOR NEW PROFESSIONAL SESSION</b></p> <p>221. Things They Didn't Teach You in Grad School</p>	<p><b>3:00PM - 4:00PM CLOSED MEMBER GROUP MEETING</b></p> <p>ISPOR Columbia Chapter Meeting</p>
<p><b>11:00AM - 12:00PM EXHIBIT HALL THEATER</b></p> <p>213. The Day After Tomorrow: Evidence, Values, and Market Access After the IRA</p>	<p><b>1:00PM - 2:00PM SPOTLIGHT SESSION</b></p> <p>223. Larger, Deeper, and in Real Time: Applications of Machine Learning and Natural Language Processing on Electronic Health Records to Learn From the Patient Journey at Scale</p>	<p><b>4:00PM - 4:00PM MEET AND GREET WITH STUDENTS AND NEW PROFESSIONALS IN HEOR</b></p> <p>The Global Research Team will provide an introduction to the ISPOR Student Network and New Professionals Network for those interested in joining or learning more.</p>
<p><b>11:00AM - 12:00PM DISCUSSION GROUPS</b></p> <p>218. Is There Room for Patient-Centered Value Assessment in Medicine Regulation and State Prescription Drug Affordability Board Processes?</p> <p>219. A Comparison of HEOR Research and Academic Analytics</p>	<p><b>1:00PM - 2:00PM PODIUM SESSION</b></p> <p>222. Factors and Community Preferences for Decision Making in Healthcare</p> <p>223. Economic Considerations of Digital Health Technologies</p>	<p><b>4:00PM - 5:00PM MEMBER GROUP MEETING</b></p> <p>Real-World Evidence Special Interest Group Open Meeting</p>
<p><b>11:00AM - 12:00PM EDUCATIONAL SYMPOSIUM</b></p> <p>220. Assessing the Impact of COVID-19 and the Effects of COVID-19 Infection on Patients-Reported Outcomes: Findings from a Nationwide Retail Pharmacy Text Database</p> <p>221. Exploring the Inflation Reduction Act</p>	<p><b>1:00PM - 2:00PM SPOTLIGHT SESSION</b></p> <p>224. Larger, Deeper, and in Real Time: Applications of Machine Learning and Natural Language Processing on Electronic Health Records to Learn From the Patient Journey at Scale</p>	<p><b>4:00PM - 5:00PM BREAKOUTS (IF, WS &amp; OR)</b></p> <p>246. A Debate on How Best to Value and Pay for Cell and Gene Therapies: Should Cost Savings Be Shared With the Health System and Society?</p> <p>247. Are Discrete-Choice Experiments Preferable to Time Trade-Off for Health State Valuation?</p> <p>248. What is the Value of Real-World Evidence for Decision Makers?</p> <p>249. Why is Specialty Drug Coverage Becoming More Restrictive?</p> <p>250. Accounting for Equity in Health Technology Assessment</p>
<p><b>11:00AM - 12:00PM SPUR FORUMS</b></p> <p>215. Assessing Real-World Data from Electronic Health Records (EHR) for HTA</p> <p>216. Using Clinical Outcome Assessments (COAs) in Your Research Study Does Not Necessarily Make it Patient-Centric</p> <p>217. Using HEOR Methods for Improving the Implementation of Value-Based Healthcare</p>	<p><b>1:00PM - 2:00PM PODIUM SESSION</b></p> <p>222. Factors and Community Preferences for Decision Making in Healthcare</p> <p>223. Economic Considerations of Digital Health Technologies</p>	<p><b>4:00PM - 5:00PM MEMBER GROUP MEETING</b></p> <p>New Professionals Meet-Up Meeting</p>
<p><b>11:00AM - 12:00PM MEMBER GROUP MEETING</b></p> <p>Members Special Interest Group Open Meeting</p>	<p><b>1:00PM - 3:00PM PM COFFEE BREAK</b></p> <p>1:00-3:00 in the Exhibit Hall</p>	<p><b>4:00PM - 5:00PM MEMBER GROUP MEETING</b></p> <p>Precision Medicine and Advanced Therapies Special Interest Group Open Meeting</p>
<p><b>12:00PM - 12:00PM EXHIBIT HALL THEATER</b></p> <p>222. Developing Fit-for-Purpose External Control Arms to Optimize Submissions to Regulatory and Health Technology Assessment Agencies</p>	<p><b>1:00PM - 2:00PM MEMBER GROUP MEETING</b></p> <p>224. Exploring Opportunities for RWE Generation Within a Hybrid Data Ecosystem</p>	<p><b>4:00PM - 5:00PM PODIUM SESSION</b></p> <p>251. Health Policy and Pricing</p> <p>254. Patient Experience Data in Regulatory Decision Making and Value Assessment</p>


<p><b>Wednesday, May 10</b></p> <p><b>7:00AM - 8:00AM ADVANCED COFFEE SERVICE</b></p> <p><b>7:00AM - 7:00PM REGISTRATION HOURS</b> (Supported by Global Research Division)</p> <p><b>8:00AM - 11:00AM BREAKOUTS (IF, WS &amp; OR)</b></p> <p>205. Why Should Pay for Medication Adherence Enhancing Interventions and What Are They Paying for?</p> <p>207. Quantitative Bias Analysis in Practice: Exploring the Role and Role of Applications to Comparative Effectiveness Studies</p> <p>202. From Concept to Practice: How to Successfully Design a Feasible Outcomes-Based Contract in Oncology?</p> <p>203. Incorporating External Evidence into Substitution: Making Sense of Seemingly Endless Options</p> <p>204. Routing RWE Sources in HTA Submissions: What Standard of Care is Now Established: How to Reduce Variance Your Shortcomings</p> <p>206. What Do Patients Consider "Meaningful Change"? Use of Qualitative Methods to Inform Meaningful When Patients Change</p> <p><b>8:00AM - 10:00AM BREAKFAST BREAK WITH EXHIBITORS</b> (Use the Exhibit Hall to brainstorm opportunities with exhibitors. Enjoy complimentary breakfast, coffee and coffee and refreshment service.)</p> <p><b>8:00AM - 11:00AM POSTER AND CHART HALL OPEN</b></p> <p><b>8:00AM - 11:00AM POSTER SESSIONS</b></p> <p>Clinical Outcomes</p> <p>Economic Evaluation</p> <p>Epidemiology &amp; Public Health</p> <p>Health Policy &amp; Regulatory</p> <p>Health Service Delivery &amp; Practice of Care</p> <p>Health Technology Assessment</p> <p>Medical Technologies</p> <p>Methodological &amp; Statistical Research</p> <p>Organizational Practices</p> <p>Patient-Centered Research</p> <p>Real-World Data &amp; Information Systems</p>	<p><b>9:00AM - 9:00AM PODIUM SESSION</b></p> <p>Budget Impact Analysis of Health Interventions</p> <p>208. PROs and Patient Experiences in Oncology and Rare Diseases</p> <p><b>9:00AM - 9:45AM EXHIBIT HALL THEATER</b></p> <p>207. Bench-to-Practice: Exploring Real-World Evidence of COVID-19 Vaccines</p> <p><b>10:00AM - 11:00AM BREAKOUTS (IF, WS &amp; OR)</b></p> <p>209. Are There Clear Criteria for Whether Real-World Data Sources Are Regulatory-Grade?</p> <p>210. Boosting Caregiver Role in Measuring the Value of New Treatments in Rare Diseases</p> <p>211. Improving Coordination Between the FDA and CMS: Exploring Potential Policy Solutions to Improve Patient Access to Drug-Granted Accelerated Approval</p> <p>212. Conceptual Modeling in HTA for Long-Term Health Conditions: A Missing Piece of the Puzzle?</p> <p>213. Does Geography Affect Health? Insights Derived From Integration of Geography-Based Social Determinants of Health With Patient-Level Real-World Data</p> <p><b>10:00AM - 11:00AM PODIUM SESSION</b></p> <p>214. Budget Impact Analysis of Health Interventions</p> <p>215. Impact of Adherence and Intervention on Health Outcomes and Cost</p> <p><b>10:00AM - 11:00AM SPOTLIGHT SESSION</b></p> <p>208. Apples and Oranges in the Context of Anchored Indirect Treatment Comparisons - Is There More to It Than Effect Modifiers?</p> <p><b>11:00AM - 11:30AM BREAK</b> (11:00-11:30 in the Exhibit Hall)</p> <p><b>11:30AM - 12:45PM PLENARY SESSION</b></p> <p>216. Closing Plenary Session</p>
--	---



大會報到處




大會電子報到系統



壁報展示及廠商攤位



會議討論



參加海報展